about
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaCancer immunotherapy: moving beyond current vaccinesDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyIL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cellsGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensAdoptive cell transfer: a clinical path to effective cancer immunotherapyT helper 17 cells promote cytotoxic T cell activation in tumor immunityWnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsCancer regression in patients after transfer of genetically engineered lymphocytesCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaHuman memory T cells: generation, compartmentalization and homeostasisLineage relationship of effector and memory T cellsIdentification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingCancer therapy using a self-replicating RNA vaccineA human memory T cell subset with stem cell-like propertiesAdoptive immunotherapy for cancer: harnessing the T cell responseCish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneTSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentationSelf-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyViral sequestration of antigen subverts cross presentation to CD8(+) T cells.Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumorsNaive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsAcquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsBig bang theory of stem-like T cells confirmed.Adoptive cell transfer as personalized immunotherapy for human cancer.Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunityTh17 cells are long lived and retain a stem cell-like molecular signatureHierarchy, tolerance, and dominance in the antitumor T-cell response.Paths to stemness: building the ultimate antitumour T cell.Memoirs of a reincarnated T cell.Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.Super-enhancers delineate disease-associated regulatory nodes in T cells.Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscapeProspects for gene-engineered T cell immunotherapy for solid cancers.Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.
P50
Q24530100-F00AE338-16A9-4E7A-84EF-65B40975384BQ24548019-04AFEBC4-8F35-4047-9CE0-7396B45815AEQ24548229-44AEB24E-24F8-4002-A8BA-70A0614B9B76Q24596055-6B8489AE-39BA-4C9F-AE45-DFB293094922Q24621753-647E060E-086B-4124-AF1D-63463252D115Q24623215-76FB949E-824D-478B-BC2A-B89A2DFA69E5Q24644442-F66C027F-ACF8-47C2-8052-C6C35E7A13EDQ24644774-0D91290A-F74B-4B34-8393-0779E4492D48Q24646584-538893BC-65AD-458C-993C-451DEA192982Q24651232-79CF26B9-C0CB-4655-8E6F-66F3D114FAD6Q24654976-6B28CD49-5CCA-4226-BC72-A516F17FFEADQ24676216-AA546E0E-89D0-4825-871E-F07446C5273EQ24679736-F3880B1D-A5EF-4F05-995A-6AC967EEFEB6Q26851748-F744F746-9F8B-462E-B844-C3880091FF4CQ27026665-2FE27545-9A36-4185-A064-0BBD147C1254Q27334215-C670ADF8-9E36-4D6E-8567-B430E1EB0733Q27481056-0874CE49-3136-4BF1-BDA6-946B63DFC46FQ28248395-99DBA182-23FA-449E-9C9F-34D79CF67E74Q28262548-2B544672-36B4-403A-9A10-E1402E07B5DAQ28269352-5A80839B-9A41-4BDB-9B50-827CC2C25C43Q28553703-7B0846EE-50DF-4D2A-9C36-0D2566492E91Q28589031-DF15C355-8951-4FED-ABCB-1156CFFEE490Q30305530-5FACB2F2-2BC1-4041-814B-73743B9318CAQ33455511-757C9E8E-0164-4F32-93A2-1B8C298700EAQ33606161-450678EE-508B-410C-8DDF-C3EC7C1B21ECQ33730129-74F8A17E-42F1-471D-99DB-C273C41139E8Q33730171-D334A526-A609-4BE3-84F1-DAF4237246D4Q33831940-BDC61306-C862-4A94-895D-E1BE5A28E309Q33948677-34E9D755-DD43-496D-AD3B-1F40297B6FDFQ34043643-AB5BFA10-4C5F-4D7A-91CC-3350D93C3D1AQ34046869-C46B2613-CEAB-4220-9DA0-DB68DFC4304AQ34241261-AE0091D9-C806-4942-B2BB-54D4572F15B0Q34275036-ED9D0A76-6A1D-4BE6-A483-6DC1C6CE2E74Q34300932-CDC9A567-F20C-4937-8AC9-A8C4D44AB938Q34320905-34D9C939-D046-4257-8549-10AFD734199BQ34422330-45E8C7AF-7454-448E-8C74-DB7551FA8062Q34463140-7D539777-0027-4BBD-97D9-DC8F17228668Q34473737-05D7B5D0-63A6-47AE-83EA-D09FBA1752CDQ34507561-8131DAE6-FC3F-45FC-91B3-3EE1C3B21822Q34538613-430919A7-4B7E-4516-8B74-0580BE4CCA51
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas P Restifo
@nl
Nicholas P Restifo
@sl
Nicholas P. Restifo
@en
Nicholas P. Restifo
@es
type
label
Nicholas P Restifo
@nl
Nicholas P Restifo
@sl
Nicholas P. Restifo
@en
Nicholas P. Restifo
@es
prefLabel
Nicholas P Restifo
@nl
Nicholas P Restifo
@sl
Nicholas P. Restifo
@en
Nicholas P. Restifo
@es
P106
P1153
7006680937
P21
P2798
P31
P496
0000-0003-4229-4580